Penny and pound wise: Pharmacoeconomics from a governmental perspective

PharmacoEconomics

Volumn 23, Issue 3, 2005, Pages 219-226

  Van Oostenbruggen, Mike F ^a   Jansen, Ronald B ^a   Mur, Katja ^a   Kooijman, Huib ^b  

^a Ministry of Health Welfare and Sport Netherlands   (Netherlands)

^b PHARMERIT INTERNATIONAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; GOVERNMENT; HEALTH CARE COST; MEDICAL RESEARCH; NETHERLANDS; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

ECONOMICS, PHARMACEUTICAL; EUROPEAN UNION; GUIDELINES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NATIONAL HEALTH PROGRAMS; NETHERLANDS;

EID: 18644374238     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523030-00003     Document Type: Review

References (24)

1. Ministerie van Volksgezondheid Welzijn en Sport. Medicines policy in The Netherlands: International Publication Series health, Welfare and Sport no. 15. The Hague: Ministry of Health, Welfare and Sport, 2003
2. Kostenbeheersing in de zorg, Kamerstuk 24124 nr 39. The Hague: Tweede Kamer der Staten-Generaal, 1996
3. Vaststelling van de begroting van de uitgayen en de ontvangsten van het Ministerie van Volksgezondheid, Welzijn en Sport (XVI) voor het jaar 1997, Kamerstuk 25000 xvi nr 71. The Hague: Tweede Kamer der Staten-Generaal, 1997
4. Richtlijn voor farmaco-economisch onderzoek, Brief van de minister van Volksgezondheid, Welzijn en Sport aan de voorzitter van de Ziekenfondsraad. The Hague, Ministry of Health, Welfare and Sport, 1997
5. Riteco JA, de Heij UM, Van Luijn JCF, et al. Dutch guidelines for pharmacoeconomic research. Amstelveen: College voor Zorgverzekeringen, 1999
6. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002; 20 (7): 443-54
7. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. Amstelveen: College voor Zorgverzekeringen, 2004
8. College voor Zorgverzekeringen, CVZ Farmaco-economisch rapportpharmacoeconomic reports Thyrogen®. Amstelveen: College voor Zorgverzekeringen, 2003 [online]. Available from URL: http://www.cvz.nl/ resources/cfh-0209thyrogenfer tcm13-1771.pdf [Accessed 2004 Dec 17]
9. van Luijn JCF. CFH-Rapport risperidone depot (Risperdal Consta®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2003 [online]. Available from URL: http://www.cvz.nl/resources/cfh03-03risperidondepot- FE_tcm13-2195.pdf [Accessed 2004 Dec 17]
10. Toenders WGM. CFH-Rapport clopidogrel (Plavix®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-06%20clopidogrel%20FER_tcm13-6750.pdf [Accessed 2004 Dec 17]
11. Toenders WGM. CFH-Rapport vardenafil (Levitra®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh03-20%20vardenafil%20FER_tcm13-6806.pdf [Accessed 2004 Dec 17]
12. Toenders WGM. CFH-Rapport eplerone (Inspra®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-26%20eplerenon%20FER_tcml3-9527.pdf [Accessed 2004 Dec 17]
13. Toenders WGM. CFH-Rapport pimecrolimus (Plavix®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-01%20pimecrolimus%20FER_ tcm13-6084. pdf [Accessed 2004 Dec 17]
14. Toenders WGM. CFH-Rapport Asi-colon (Oncovax®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-oncovax%20FER_tcm13-6527.pdf [Accessed 2004 Dec 17]
15. Toenders WGM. CFH-Rapport omega-3-vetzuren (Omacor®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-13-omega-3-vetzuren-FER_tcm13-7841. pdf [Accessed 2004 Dec 17]
16. van Luijn JCF. CFH-Rapport risperidone depot (Risperdal Consta®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2003 [online]. Available from URL: http://www.cvz.nl/resources/cfh03-03risperidondepot- FE_tcml3-2195.pdf [Accessed 2004 Dec 17]
17. Hill SR, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116-21
18. A proposal for methodological guidelines for economic evaluation of pharmaceuticals. Brussels: Belgian Society for Pharmacoepidemiology, 1995
19. Amtliche Verlautbarungen der osterreichischen Sozialversicherung; Verfahrensordnung (no 100) zur Herausgabe des Heilmittelverzeichnisses. Vienna: Der Hauptverband der österreichischen Sozialversicherungsträger, 2003
20. Baltic guidelines for economic evaluation of pharmaceuticals. Health authorities from the Baltic countries, 2002 [online]. Available from URL: http://www.zca.gov.lv/docs/new2002/doc24-1.pdf [Accessed 2004 Aug 8]
21. General guidelines for economic evaluation from the Pharmaceutical Benefits Board LNFAR. Solna: Swedish Pharmaceutical Benefits Board, 2003 [online]. Available from URL: http://www.lfn.se/upload/English/ENG_lfnar2003- eng.pdf [Accessed 2004 Aug 8]
22. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Oslo: Norwegian Medicines Control Authority, 2000 [online]. Available from URL: http://www.legemiddelverket.no/eng/reg/ pharmacoeconomic-analysis-guidelines.htm [Accessed 2004 Aug 8]
23. Dickson M, Hurst J, Jacobzone S. OECD health working papers no. 4 survey of pharmacoeconomic assessment activity in eleven countries. France: OECD, 2003 [online]. Available from URL: http://www.oecd.org/dataoecd/27/25/2955828.pdf [Accessed 2004 Aug 8]
24. Bentkover JD, Corey R. Effective utilization of pharmacoeconomics for decision makers. Dis Manage Health Outcomes 2002; 10 (2): 75-80